Tempus Ai,Inc.-Tempus AI signals sustained 25% genomics growth target through 2028 while achieving first positive adjusted EBITDA (NASDAQ:TEM)

Tempus AI signals sustained 25% genomics growth target through 2028 while achieving first positive adjusted EBITDA (NASDAQ:TEM)

Tempus Ai,Inc.(US:TEM) Seeking Alpha·2025-11-05 00:07

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...